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and m~llna class (75% class Ill or IV). While there was less 3 vessel/lalt main 
in PTCA patients (56% vs 75%, p < 0,0001), ejection fractions were similar. 
Comparison of Results and Costs are shown in the table. 
The initial advantage of PTCA over redo CABG in terms of mortality, and 
myocardial Infarction was largely lost by 5 years. There were more additional 
procedures and moun'ant angina with PTCA. The initial cost advantage 
of PTCA may also be lost because of additional procedures. Choice of 
procedure should be made by careful clinical assessment, as a choice of 
therapy to minimize cost is unclear and cannot be justified. 
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~'~ Hearlt Rate-Lowering Calcium Channel Blockers 
(Dlltiazem, Verapamli) Do Not Adversely Affect 
Long-Term Cardiac Death or  Non-Fatal Infarction in 
Post-lntar~tlon Patlents: Data Pooled From 3 
Randomlzed, Placebo-Contro!led Cllnlcal Trials o f  
5,677 Palfents 
William E. Beden, Franz H. Messedi, Jergan Fischer Hansen, Kenneth 
B. Schechtman. Boston VA. Medical Center, Boston, MA 
Recent meta-analyses and case-control studies purport to show harm as- 
sociated with the use of short-acting calcium channel blockers (CCB)--- 
particuiarly dihydropyddines--io beth hypertensive and ischemio patient sub- 
sets, and cite the absence of evidence-based medicine ragmding long-term 
safety and efficacy. Reports which impugn CCB use are predicated on ret- 
respecllve, non-randomized, unbllnded ata sources with inherent treatment 
biases, and utilize pooled data of divergent CCB agents which may either io- 
crease (dibydropyrldinas) or decrease (diltiazem/verapamil) heart rata (HR). 
We performed a pest h0c analysis of pooled data obtained from 5,677 post- 
MI patients randomized to a HR.iowedng CCB or placebo (P) in the first 
and second Danish Verapamif Infamtion Tdals (DAVIT h n = 1,436; DAVff-II: 
n = 1,775) and the Multicanter Diltiazem Poet-Infarction Tdal (MDPi'r: n = 
2,4¢36). Dudng a mean follow-up of 550 ± 376 days, the combined clinical 
evnot (cardiac death [CD] or MZ) rate was 18% In the CCB group (515/2,827) 
vs, 20=/0 in the P group (582/2,349), p = 0.018 (Kaplan-Maler comparisons; 
generalized Wiiooxon test). Actuarial evant-free survival (CCB vs P groups, 
respectively) was 0.89 vs. 0,87 at 6 mo, 0.85 vs. 0.82 at 12 too, 0.79 vs. 0.77 
at 24 too, and 0.72 vs. 0.69 at 48 mo. After adjusting for relevant covadatas 
(age, gender, diabetes, pdor MI, hypertension) using Cox regression analy- 
ses, HR-iowenng CCBa were associated with significantly reduced CD or MI 
rates (CCB vs P dsk ratio [95% Cl] = 0.88 [0 77-0.99], p = 0,035). 
Conclusions: 1 ) HR-Iowedng CCBs do not increase cardiac events in post- 
MI pts dudng long-term follow-up; 2) such pooled data from randomized, 
double-blind, placebo-controlled trials underscore the importance of differen- 
tiating CCB agents which raise or lower heart rate. 
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~8"0"~ Long-Term Safety of  Cal©ium Antagonists: 
Reassessment o l the  Furberg Hypothesle 
Franz H. Messedl, Uonel H. Opie, Richard Chambers. Ochsner Meal/ca/ 
Institutions, New Orleans, LA; C, apatown, South Africa 
In ;1 recent mate-analysis, Fu¢cerg et al (Circulation, Sept. 1, 1995) I~zve 
purported to show a dose-related Increase in mortality with short-acting 
nifedlpine In patients with acute myocardial infarction, Since there were sev- 
eral misquotation errors (e.g., dose, total number of patients) when compared 
with the .original publications, we recalculated the mete-analysis in two In- 
dependent statistical centers. Whether a study dealing with stable coronary 
artery disease (INTACT) should be included In a mote-analysis on unstable 
angina and acute myocardial infarction is controversial. Hence, we present 
the data with and without INTACT. 
Results were as follows: 
Source Nifedlplne Control RR (95% CI) P' 
death~pts deaths/pts 
Fud0erg at el., Circulation 335/4171 274/4183 1.16 (1.01-1.33) 0.01 
Furberg et el., recak:ulsted 390/5301 339/5329 1.16 (1.00-1.34) 0.05 
Originals (with INTACT) 320/5109 291/5160 1.11 (0.94-.1.32) 0.19 
Originals (without INTACT) 308/4895 289/4949 1.08 (0.91-1.28) 0.36 
*Chi square test for listed proportions for comparison only. 
Conclusion: The mete-analysis of Furberg at al is incorrect; there is no 
overall significant increase in mortality in the nifedipine group compared with 
the control group. Logistic regression analysis showed neither a group nor a 
dose rciationshtp to mortality. Although the observed increase in mortality in 
the nifedipina group was not statistically significant, our data do not dispute 
the common clinical contention that acute release nifedipine should not be 
used in acute myocardial infarction. 
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8~"3- -1  Prognosia of  Diabetic Patients After Myocardial 
Infarction: Effect o f  Early Treatment With 
ACE-Inhlbitars 
Giullo Zuanatti, Roberto Latini, Aldo P. Maggioni, Luigi Santoro, 
MariaGrazia Franzosi, Gianoi Tognoni, on behalf of the GISSI-3 
Invasf~ors. ANMCO and Istituto M. Negri, Italy 
It is recognized that diabetic pts have ;1 higher morbidity and mortality after 
myocardial infarction (MI). The effect of novel therapeutic strategies including 
ACE-inhibitors (ACE-0 in these pts is unknown. We analyzed the effect of 
an early treatment with llslnopdl (L) in an unselected population of diabetic 
pts wi~ acute MI enrolled in the GISSI-3 study. L (5 mg up to 10 mg) was 
started within 24 hrs from the onset of symptoms. A total of 2790 pts had 
;1 history of defined diabetes, with clinical and demographic harastadstics 
balanced between groups of treatmanL The 6-week mortality of pts with 
;z history of non-insulin (NIDD) and insulin dependent (IDD) diabetes was 
markedly reduced by L as shown in the table. 
NIDD IDD 
No-L L No-L 
n. of pts 1164 1130 242 254 
mortal'try 10.5% 7.7% 21.1% 11.8% 
% reduction -26.7% -44.1% 
OR (95% el) 0.71 (0.54-0.95) 0.51 (0.31.-0.81) 
The treats~aflt was associated with an increased incidence of in-hospital 
persistent hypotonsion (6.5 vs 4.3% in NIDD, p < 0.05 and 9.1 vs ¢5°/= in 
IDD, pNS) and renal dysfunction (3.2 vs 1,4% in NIDD, p < 0.01 and 3.9 vs 
1.6°/o in IDD p Ns), similar to that observed in non-diabetic pts. 
In conclusion, (1) in diabetic pts with acute MI early treatment with lisinopdl 
is associated with ;1 markedly reduced 6-week mortality (2) the beneficial 
effect is evident in beth NID and ID diabetes.,. 
If confirmed in other studies, these data would support a widespread and 
early use of ACE-i in diabetic pta with acute MI. 
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[ " ~  Carvedilol Prevents Rem.........~det!!~ and Improves 
Prognosis in Patients With Left Ventdcuiar 
Dysfunction Fol lowing Acute Myocardial Infarction 
Roxy Senior, Sumit Bas'J, Avijit Lahid. Northwk~ Park Hospital, Harrow, UK 
Left vantdcutar (LV) dysfunction following acute myocardial infarction (AMZ) 
affects prognosis advemely possibly due to LV remodelling. Carvediiol (C) is 
a multiple acting, non-selsotive ~-blocker with additional vasodiiatory prop- 
er~as. To assess the role of C on LV remodalllag and its effect on prognosis 
(adverse cardiac events) 49 consecutive patients (pto) with LV ejection free- 
,on < 45% (34 ± 8%, moan 4- SD) following AMI were evaluated in a 
double-blind, randomised, placebo (P) controlled study. [=Is received medi- 
cation immediately following thrembolysis and continued for 6 months dudng 
which they were followed up. 2D Echoca~hy (Echo) was per~nned at 
p re -d~ 0/1) (8-.10 days) and at 3 months 0/2). Parametam evaluated 
were: LV ejection fraction (LVEF)%, end-systolic (ESV) and end-cr~'tdiio 
volumes (EOV) (mis), wall motion score index 0NMSI) and regional (site of 
infarct) wall motion score (RWMS). Wall motion score was graded from 0 
(normal) to 4 (dysldnstio). Analysis of variance was performed. 
ESV EDV WMSI RWMS 
Vl V2 V1 V2 Vl V2 V1 V2 
C 78±22 74:1:30 121±29 122+34 1.44-0.5 1.0±0.7 124-3 84-4 
P 914-32 1004-47 1374-38 1484-54 1.6:E0.4 1.44-0.6 134-3 11:1:5 
p value 0.01 0.01 0.03 0.0~ 
There were significantly less cardiac events (p = 0.04) with C (21%) 
compared to P (52%). Thus, C prevented LV remodelling and improved 
prognosis in pts with AMI and LV dysfunction. 
